The FDA issued a letter to the company declaring that it will not accept a letter of intent for the company's Parkinson's exam.
The filing describes a device with an array of sensors that would be able to reduce or stabilize involuntary movement in an adjacent joint or entire limb.
The two companies are working with the Parkinson's Center of Excellence at King's College Hospital in London to develop a software that can detect signs of Parkinson's within minutes.
The device uses vibrating motors, similar to those found in mobile phones, to distract the brain into focusing on something other than trying to control the patient's limbs.
The experiential technology can recreate disease symptoms to put physicians and caregivers in patients' shoes.
Vitruvian Networks, will serve as a network orchestrator for therapeutic companies with powerful business intelligence and data analytics capabilities.
Called GADGET-PD, the trial will use wireless sensors and genetic sequencing to determine if a patient has essential tremor (ET) from Parkinson's disease (PD).
The two parties will develop an experimental IoT system that uses connected devices to enable remote measurement of health and quality of life in real-time.
The dataset has information captured from more than 9,500 people to help speed scientific progress toward treatments for people with Parkinson's disease.
The user wears a ring during the day while the information about his/her movement is transferred via Bluetooth to an iOS app, and then to the cloud.
12Page 1 of 2